There are 2789 resources available
Introduction
Presenter: Jose Martin-Moreno
Session: Prevention strategies
Resources:
Slides
Effect of primary prevention for the general population
Presenter: Carolina Espina
Session: Prevention strategies
Resources:
Slides
Webcast
Relevance to address obesity
Presenter: Heinz Freisling
Session: Prevention strategies
Resources:
Slides
Webcast
Customized intervention: The case of acetylsalicylic acid and Lynch syndrome
Presenter: John Burn
Session: Prevention strategies
Resources:
Slides
Webcast
Introduction
Presenter: Christopher Booth
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Webcast
The limitations of clinical evidence from trials when data presented for HTA: Immature survival data, selected patient populations, phase II data for uncommon cancers etc...
Presenter: Nathan Cherny
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast
Real-world evidence and regulatory drug approval
Presenter: Christopher Booth
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast
RWE: When should it be used by EMA?
Presenter: Francesco Pignatti
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast
Challenges of collecting RWE: Limitations of administrative data sets, complex methodological issues, responsibility for collecting data
Presenter: Valery Lemmens
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast
Introduction
Presenter: Solange Peters
Session: Beating cancer at the EU level: Influential policies changing the paradigm of the cancer (treatment) lifecycle
Resources:
Slides